A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03927456 |
Recruitment Status : Unknown
Verified June 2020 by Jiangsu HengRui Medicine Co., Ltd..
Recruitment status was: Active, not recruiting
First Posted : April 25, 2019
Last Update Posted : June 3, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Advanced Breast Cancer | Drug: SHR6390 Drug: Placebo Drug: Fulvestrant | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 357 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase III Study to Evaluate the Efficacy and Safety of SHR6390 in Combination With Fulvestrant Versus Placebo Combined With Fulvesrant in Patients With HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer |
Actual Study Start Date : | June 13, 2019 |
Estimated Primary Completion Date : | December 30, 2021 |
Estimated Study Completion Date : | December 30, 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: SHR6390 + Fulvestrant
Intervention Drug: SHR6390, Fulvestrant
|
Drug: SHR6390
SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment Drug: Fulvestrant Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease |
Placebo Comparator: Placebo + Fulvestrant
Intervention Drug: Placebo, Fulvestrant
|
Drug: Placebo
Placebo 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment Drug: Fulvestrant Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease |
- Investigator-assessed PFS [ Time Frame: Up to approximately 24 months. ]Investigator-assessed Progression Free Survival
- Progression-free Survival (PFS) per RECIST 1.1 [ Time Frame: Up to approximately 24 months. ]PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review or death due to any cause, whichever occurs first.
- OS [ Time Frame: Up to approximately 2 years ]Overall Survival
- ORR [ Time Frame: Up to approximately 24 months. ]Objective Response Rate
- DoR [ Time Frame: Up to approximately 24 months ]Duration of Objective Response
- CBR [ Time Frame: Up to approximately 24 months. ]Clinical Benefit rate
- AEs and SAEs [ Time Frame: Up to approximately 24 months. ]Number of Participants With adverse events (AEs) and serious adverse events (SAEs) Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v4.03.
- Ctrough [ Time Frame: Up to 4 weeks ]Ctrough

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Has the pathologically-confirmed diagnosis of locally recurrent or metastatic, hormone-receptor positive, HER2 negative Breast Cancer.
- Age: 18 - 75 years old, postmenopausal women or prepostmenopausal women
- Received prior endocrine therapy
- One previous line of chemotherapy for advanced/metastatic disease is allowed in addition to endocrine therapy.
- Eastern Cooperative Oncology Group [ECOG] 0-1
Exclusion Criteria:
- Patients who received prior treatment with any CDK4/6 inhibitor, everolimus or fulvestant.
- Clinically significant cardiovascular and cerebrovascular diseases,including but not limited to severe acute myocardial infarction within 6 months before enrollment, unstable or severe angina, Congestive heart failure (New York heart association (NYHA) class > 2), or ventricular arrhythmia which need medical intervention.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03927456
China, Beijing | |
Chinese Academy of Medical Science | |
Beijing, Beijing, China |
Responsible Party: | Jiangsu HengRui Medicine Co., Ltd. |
ClinicalTrials.gov Identifier: | NCT03927456 |
Other Study ID Numbers: |
SHR6390-III-301 |
First Posted: | April 25, 2019 Key Record Dates |
Last Update Posted: | June 3, 2021 |
Last Verified: | June 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Fulvestrant Antineoplastic Agents, Hormonal |
Antineoplastic Agents Estrogen Receptor Antagonists Estrogen Antagonists Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |